Page last updated: 2024-12-08

gamma-glutamylglutamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gamma-glutamylglutamine: RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamma-Glu-Gln : A dipeptide obtained by formal condensation of the gamma-carboxy group of glutamic acid with the amino group of glutamine [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID150914
CHEBI ID73707
SCHEMBL ID236266
MeSH IDM0136990

Synonyms (32)

Synonym
n-gamma-glutamylglutamine
(5-l-glutamyl)-l-glutamine
C05283 ,
gamma-glutamylglutamine
gamma-glu-gln
10148-81-9
1466-50-8
glutamine, n-l-gamma-glutamyl-, l-
gamma-l-glu-l-gln
CHEBI:73707
SCHEMBL236266
h-gamma-glu-gln-oh
h-?-glu-gln-oh
h-|a-glu-gln-oh
gamma-l-glutamyl-l-glutamine
DTXSID30163415
(2s)-2-[(4s)-4-amino-4-carboxybutanamido]-4-carbamoylbutanoic acid
AKOS030525458
mfcd00038475
n2-gamma-glutamylglutamine
n-l-gamma-glutamyl-l-glutamine
h--glu-gln-oh
(s)-2-amino-5-((s)-4-amino-1-carboxy-4-oxobutylamino)-5-oxopentanoic acid
F21424
h-glu(gln-oh)-oh
Q27105013
AS-10487
(2s)-2-amino-5-[[(1s)-4-amino-1-carboxy-4-oxobutyl]amino]-5-oxopentanoic acid
(2s)-2-amino-5-[[(4s)-4-amino-4-carboxybutanoyl]amino]-5-oxopentanoic acid
l-glutamine, l-gamma-glutamyl-
CS-0059318
HY-113003

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Conjugation of PTX to the PGG polymer increased plasma and tumor Cmax, prolonged plasma half-life and the period of accumulation in tumor, and reduced washout from tumor."( Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.
Howell, SB; Jiang, N; Van, S; Vera, D; Wang, X; Yu, L; Zhao, G, 2010
)
0.36
"Incorporation of PTX into the PGG-PTX polymer significantly prolonged the half-life of total taxanes, extractable taxane, and native PTX in both the plasma and tumor compartments."( Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.
Howell, SB; Jiang, N; Van, S; Vera, D; Wang, X; Yu, L; Zhao, G, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's6 (37.50)18.2507
2000's1 (6.25)29.6817
2010's6 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.83 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]